Martindale Pharma has announced the approval and supply of Noyada in France, under an ATU de’ Cohorte (Temporary Authositaion for Use) programme which will commence in June.
Noyada is an oral liquid version of captopril used in the treatment of paediatric chronic heart failure. Cevidra Laboratories, a French-based pharmaceutical company, which specialises in ATU programmes, will distribute Noyada in France.
Martindale Pharma has also started the process to seek Marketing Authorisation Approval in France. Noyada is the only approved oral liquid formulation of captopril in Europe and has been available in the UK for two years. It’s targeted for use in children with serious cardiovascular conditions who can benefit from an oral liquid product.
Michael Harris, CEO of Martindale Pharma, commented, ‘Martindale Pharma is committed to developing innovative presentations of known drugs that improve patients’ lives and we are very pleased to have received approval to supply Noyada for paediatric patients in France.’
